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Abstract We identified alternatively spliced forms of Stat2 in 
human and mouse mRNAs. The spliced forms are generated by 
reading through the intron between exon 20 and 21, which 
correspond to the region encoding SH2 domain. The spliced 
forms contain a stop codon in SH2 domain, and therefore give 
rise to a short form of Stat2 when the mRNAs are translated. 
The putative translated proteins lack half of the SH2 domain, the 
tyrosine phosphorylation site required for dimerization (or 
oligomereization) and DNA binding, and C-terminal activation 
domain. The significance of these spliced forms is discussed. 
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the existence of other isoforms of Stat3 [19] and Stat5 [20]. 
However, there is no previous report about Stat2 (pl13) iso- 
form. 
In order to identify novel members of Stat family expressed 
in mouse liver, RT-PCR (reverse transcription-polymerase 
chain reaction) amplification was performed using degenera- 
tive primers derived from the amino acid sequences highly 
conserved among Stat family members (data not shown). 
We report here the identification of alternatively spliced forms 
of Stat2 transcript. 
2. Materials and methods 
I. Introduction 
Cytokine receptor signals are mediated by Jak family of 
tyrosine kinases and Stats (signal transducers and activators 
of transcription) [1]. IFN-~ signaling involves phosphoryla- 
tion of Statl [2] and Stat2 [3,4] through Jakl [5] and Tyk2 
[6], leading to formation of  the transcription factor IFN-stim- 
ulated gene factor 3 (ISGF3) [7,8] that binds to the IFN-stim- 
ulated response elements (ISREs). The ISGF3 transcription 
factor is composed of three subunits: Statlot/13 [2], Stat2 and 
p48 DNA binding protein [9]. On the other hand, IFN-y in- 
duces formation of the y-activated transcription factor (GAF) 
consisting of Statlc~ homodimer, which binds to the IFN-y 
activation site (GAS) elements. 
A src homology 2 (SH2) domain of each Stat family mem- 
ber has a crucial role in dimerization (or oligomerization) of 
the activated Star [10] as well as in recognition of  the phos- 
photyrosine of the activated receptor [11,12]. Ligand-specific 
activation of Stats is shown to be determined by specific dock- 
ing interaction between a Stat SH2 domain and a phospho- 
tyrosine-containing sequence in the receptor. 
Several alternatively spliced forms of Stat family are re- 
ported. Alternative splicing of Statl at 3' end results in Stat l~ 
(p91) and Stat 1 [~ (p84) [13,14]. Stat I I~, which lacks C-terminal 
39 amino acid residues of Statlc~ has no activity in IFN-y 
dependent transcription, although Stat la  is able to mediate 
the transcription signal [15]. The Stat313 [16] which lacks C- 
terminal 55 amino acid residues of Stat3/APRF [17,18] but 
contains novel 7 amino acid residues at its C-terminus was 
recently cloned by use of two hybrid systems. Unlike Stat3, 
Stat31~ can synergize with c-jun in transcription activity. Some 
other reports by use of Western blotting techniques uggested 
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2.1. Cell culture and isolation of RNA 
The human hepatoblastoma cell line Hep3B [21] and the human 
fibroblast cell line HeLa were cultured in Dulbeceo's modified Eagle's 
medium (DMEM) supplemented with 10% fetal bovine serum, high 
glucose (4.5 g/l), penicillin, and streptomycin. HeLa cells were stimu- 
lated with IFN-~ (1000 U/ml) (Collaborative Research Inc., Bedford, 
MA) for 0, 0.5, 2 and 6 h. The cells were washed with PBS (phos- 
phate-buffered saline) and lysed with the denaturing solution (4 M 
guanidine thiocyanate, 25 mM sodium citrate (pH 7), 0.5% sarcosyl, 
0.1 M 2-mercaptoethanol), and total RNAs at various time points 
were prepared by acid guanidine-phenol chloroform (AGPC) method 
[22]. The contamination of genomic DNA was eliminated by RNase- 
free DNase I (Stratagene, La Jolla, CA) treatment. 
Mouse total RNAs were prepared from various tissues as described 
above. 
2.2. RT-PCR analysis 
First-strand cDNA was prepared from 1 2 Jig total RNA of var- 
ious mouse tissues and the human cell lines using an oligo d(T)15 is 
primer and the Superscript II reverse transcriptase (Life Technologies 
Inc., Gaithersburg, MD). To amplify the mouse eDNA of Stat2 SH2 
region, a sense primer mlL (5'-GGCATTACTTGTTCTTGGGTG- 
GAGCACC-3') at exon 20 and an antisense primer m2L (5'- 
CACTTCCTTGGTGTAGGGCTGCACTGAG-3') at exon 21 were 
used in RT-PCR. To amplify the human eDNA of Stat2, a sense 
primer hl (5'-AGTTGGTACATGACCACC-3') at exon 19 and an 
antisense primer h2 (5'-AGCGCAGTGGGTTTTCAG-Y) at exon 21 
were used in RT-PCR. To amplify only the alternatively spliced form 
of human Stat2, a sense primer hl (described above) and an antisense 
primer hint (5'-AGTCCCAAACCAGCTGAG-3') at the normal in- 
tron were used in RT-PCR. All polymerase chain reactions (PCR) 
were performed in a final volume of 50 lal containing cDNA aliquot 
corresponding to 25 or 150 ng of total RNAs, 20 mM Tris (pH 8.4), 
50 mM NaCI, 1.5 mM MgCI2, 1 mM of each dNTP, 40 pmol of each 
primer, and 1.25 U Taq polymerase (Takara Shuzo Inc., Japan). The 
PCR conditions to amplify human cDNAs were 35 cycles of 20 s at 
94°C, 30 s at 62°C, and 1 min at 72°C by Gene Amp PCR System 
9600 thermal cycler (Perkin Elmer, CT). The PCR conditions to am- 
plify mouse cDNAs were 35 cycles of 20 s at 94°C, 30 s at 67°C, and 
30 s at 72°C. All PCR reactions described in this study had an initial 
denaturing step of 1 min at 94°C and a terminal extension step of 
7 min at 72°C. All PCR products were electrophoresed in a 2% agar- 
ose gel stained with ethidium bromide and photographed. 
The amplified clones were isolated from the gels and subsequently 
cloned into T-vector (Novagen, Madison, WI). Sequencing of the 
subclones was performed by DNA autosequencer 373A (Applied Bio- 
systems Inc., Foster City, CA) using dye terminatation method. 
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2.3. Genomic organization ofSH2 domain of Stat2 
Mouse and human genomic DNAs were isolated by a general pro- 
cedure [23] and subjected to PCR. To clone mouse genomic DNA, a 
sense primer olL at exon 20 and an ant*sense primer m2L at exon 21 
were used in PCR. To clone human genomic DNA, a sense primer 
hlL (5'-ATTACCTGCTCCTGGGTGGAGCACCAG-3') at exon 20 
and an ant*sense primer h2L (5'-CACCTCCIq'CGTGTACGGTTG- 
CACAGAG-3') at exon 21 were used in PCR. The PCR conditions to 
amplify human and mouse genomic DNAs were 35 cycles of 20 s at 
94°C, 30 s at 68°C, and 1 min at 74°C after hot start by Cetus 480 
thermal cycler (Perkin Elmer). Both PCR products are electrophor- 
esed in an 1% agarose gel and isolated, subsequently the purified PCR 
products were subcloned into T-vector and sequenced as described 
above. 
3. Results 
3.1. Alternative splicing of Stat2 transcript 
We identified alternatively spliced forms of Stat2 transcript 
by use of RT-PCR technique. Several extra bands were ob- 
served in PCR products derived from mouse tissue cDNAs 
using primers ro lL  at exon 20 and m2L at exon 21 (Fig. 1A). 
Each band was cloned and subjected to sequencing analysis. 
Comparison of the sequences of these PCR products with the 
genomic DNA sequence around the exon/intron boundaries 
demonstrated that mouse Stat2 existed in three alternatively 
spliced forms which we named type 'a', 'b', and 'c' (Fig. 2A). 
The major PCR product was derived from a normally spliced 
form of Stat2 (p113, type 'a'), two extra products from novel 
alternatively spliced forms of Stat2 (type 'b' and 'c'). How- 
ever, both of the novel identified forms type 'b' and 'c' contain 
a translation stop codon at the same position which should 
yield the short form of Stat2. These novel identified mRNAs  
were distributed in various tissues as well as Stat2 type 'a' 
mRNA (Fig. 1A), although Stat2 type 'a' mRNA was ex- 
pressed much abundant ly in most of the tissues. 
The extra band of Stat2 was also observed in PCR products 
derived from human hepatoblastoma cell line Hep3B cDNA 
using primers hl  at exon 19 and h2 at exon 21 (Fig. 1B). The 
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Fig. 2. (A) Alternative splicing of mouse Stat2 transcript. The open 
box represents an exon. The hatched box is considered an exon if it 
is not spliced out. Short bars indicate the position of primers mlL 
and m2L used for RT-PCR analysis. An asterisk (*) indicates a 
translation stop codon. (B) Alternative splicing of human Stat2 
transcript. Short bars indicate the position of primers hi, h2, and 
hint used for RT-PCR analysis. Primers hl and h2 were used to 
amplify type 'a' and 'c' cDNAs. Primers hl and hint were used to 
amplify only type 'c' cDNA. 
sequencing of the extra band showed that it corresponded to 
mouse type 'c' mRNA (Fig. 2B). Human type 'c' mRNA was 
also detected in other cell lines such as fibroblast cell line 
HeLa and plasmacytoma cell line U266 (data not shown). 
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Fig. 1. (A) Tissue distribution of mouse Stat2 and the isoforrn 
mRNAs. Three alternatively spliced forms of Stat2 (band 'a', 'b' 
and 'c') were detected by use of RT-PCR. The size of the PCR pro- 
ducts 'a', 'b' and 'c' were 80, 160, and 269 bp, respectively. 
M = ¢X174 HaelII digest marker. (B) Two forms of human Stat2 
were detected in Hep3B cell line by use of RT-PCR. An extra 'c' 
band was observed. The size of the PCR products 'a' and 'b' were 
303 and 497 bp, respectively. 
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mouse 1" GGCGCCTTCCTGCTGCGCTrCAGTGAAACTTCTGAAGGGGGCATrACTrGTTCTFGGGTG 
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Fig. 3. Comparison of human and mouse Stat2 genomic DNA se- 
quences around exons 20 and 21. Partial genomic DNA sequences 
between exons 20 and 21 are aligned, introducing aps ( - )  to maxi- 
mize nucleic acid identity. The squared sequences written by large 
characters represent exons 20 and 21 and the other sequences writ- 
ten by small characters represent an intron. Arrows indicate the se- 
quence of primers used for cloning of genomic DNA. Under lines 
indicate splicing signals, GU-AG. Splicing signals "a' and 'b' were 
used for type 'a' and 'b' in mouse, respectively. 
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3.2. The genomic structure and putative amino acid sequence of 
human and mouse Stat2 isoforms around exon 20 and 21 
The human and mouse genomic DNA sequences were com- 
pared around exon 20 and 21 boundaries (Fig. 3). The se- 
quences of exon 20 and 21 were highly conserved, while intron 
DNA sequences between exon 20 and 21 were 70% homolo- 
gous. All the intron extremities follow the GT-AG rule [24]. 
The mouse intron DNA sequence contains two splice donor 
sites (a and b) and one splice acceptor site, whereas the human 
intron DNA sequence contains one pair of splicing signal. 
This difference of splicing signals accounts for the existence 
of three alternatively spliced forms in mouse and of two forms 
in human. 
The putative amino acid sequences of Stat2 (Fig. 4A) and 
the short form (Fig. 4B) were compared between human and 
mouse. In the short form of Stat2, 231 C-terminal amino acid 
residues were replaced by novel 32 amino acids in human and 
22 amino acids in mouse, respectively. The additional C-term- 
inal sequences of the short form were not conserved, although 
normal Star2 amino acid sequences were highly conserved 
between human and mouse. 
3.3. Induction of Stat2 and the alternatively spliced messages 
HeLa cells were stimulated by IFN-oL PCR amplifications 
were performed using two sets of primers because a large 
amount of Stat2 made it difficult to detect ype 'c' mRNA. 
RT-PCR analysis using one set of primers hl at exon 19 and 
h2 at exon 21 detected type 'a' mRNA and a faint band 
corresponding to type 'c' mRNA (Fig. 5A) whereas RT- 
PCR using the other set of primers hl at exon 19 and hint 
at the intron between exon 20 and 21 detected only type 'c' 
mRNA (Fig. 5B). The type 'c' mRNA was induced in re- 
sponse to IFN-c( as well as that of normal Stat2 mRNA. 
4. Discussion 
The alternatively splicing patterns of Stat2 described in this 
paper is different from those of the other Stat isoforrns 
[13,14,16]. The previously identified Stat isoforms are variants 
which lack their C-terminal amino acid sequences, but still 
conserving the SH3 and SH2 domain and tyrosine phosphor- 
ylation site. On the other hand, novel identified Stat2 isoforms 
are internally spliced ones, which would generate short forms 
lacking crucial regions for the Stat signaling. Such a splicing is 
reported in Ash/Grb2 [25], which is the adapter molecule with 
two SH3 and one SH2 domain between protein tyrosine ki- 
nase receptors and Ras. One of the splicing isoforms of Ash/ 
m Exon 20 Exon 21 
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human type a GTFLLRFSESSEGGITCSWVEHQDDDKVLIYSVQpYTKEVLQSLPLTEIIIRHYQLLTEENIPEN 
* *******  ******************  ******* , *************  *  * *******  
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586 596 60(5 ~ 616 6Z6 636 
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Fig. 4. Comparisons of human and mouse Stat2 putative amino 
acid sequences. (A) Putative amino acid sequences of human and 
mouse Stat2 around exons 20 and 21 were compared. Conserved se- 
quences are indicated by an asterisk (*) and a translation stop co- 
don is indicated by a sharp (#). An arrow indicates the boundary 
between exon 20 and the following intron if it is spliced out. 
(B) Putative amino acid sequences of human and mouse Stat2 short 
forms were compared. 
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Fig. 5. Induction of human Stat2 in HeLa cell line in response to 
IFN-c~. Two alternatively spliced forms of Stat2 were detected by 
RT-PCR. (A) Primers hl and h2 were used to amplify the type 'a' 
and 'c' cDNA aliquots corresponding to 25 ng of total RNA. Only 
the type a products were clearly visible. (B) Primers hl and hint 
were used to amplify only the type 'c' cDNA aliquots corresponding 
to 150 ng of total RNA. 
Grb2 (Ash-s) generates a short form lacking SH2 and second 
SH3 domain. Ash-s containing first SH3 domain is considered 
to exert an inhibitory effect by competition [25,26]. 
The biological role of the predicted short forms derived 
from alternatively spliced Stat2 message is unclear. The 
Statl and Stat2 lacking the SH2 domain and/or the tyrosine 
phosphorylation site are unable to form of ISGF3 complex 
[10], suggesting that the predicted short form could not parti- 
cipate in the formation of ISGF3 complex. The short form 
conserving N-terminal half region might exert an inhibitory 
effect as well as Ash-s does. 
We have tried to detect he predicted short forms employing 
western blotting techniques using a polyclonal antibody (San- 
ta Cruz Biotechnology Inc., Santa Cruz, CA) that recognize 
the N-terminal site of human Stat2, but we could not ensure. 
Stat313 mRNA is reported to be expressed in a low amount 
and detected only by use of RT-PCR [16] like our case. 
Although the predicted short form of Stat2 would be ex- 
pressed in low amount, it is possible that the protein has 
any function like Stat313 does. 
We further investigated alternate splicing of Stat2 in other 
regions and obtained implication of existence of a few more 
isoforms around exon 15 and 18, which appear to be derived 
by skipping of the intervening exons (data not shown). More- 
over, exon-intron organizations of Stat2 and Stat3 are quite 
similar and the boundary of exon 20 and exon 21 is located at 
the same position of amino acid sequences. However, Stat3 
was not alternatively spliced. 
In conclusion, we demonstrated that a small part of Stat2 
transcripts is alternatively spliced, which would generate a
short form lacking half of the SH2 domain, tyrosine phos- 
phorylation site, and C-terminal activation domain. The pre- 
cise role of the short form needs to be further elucidated. 
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